Introduction: S100 protein and GFAP expression in pituitary adenomas tumour cells is not well known; few correlations with other prognostic or therapeutic factors have previously been reported in pituitary adenomas. We aim to elucidate their involvement in the pathogenesis of pituitary adenomas and to establish the correlation of their expression with different growth factors and growth factor receptors known to have a prognostic and/or therapeutic role. Material and methods: Sixty-one cases of pituitary adenomas were immunohistochemically assessed for the expression of GFAP and S100 protein in both tumour cells and FS cells, in close relationship with hormone profile, and correlated with vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) expression, previously studied by our team. Results: GFAP and S100 protein were expressed both in tumour cells and FS cells. Differences between morphology, distribution, and density of GFAP+ FS cells and S100+ FS cells were observed according to the hormone profile of pituitary adenomas. GFAP and S100 protein expression in tumour cells was significantly related to hormone profile of pituitary adenomas and also with VEGF and EGFR expression. Conclusions: GFAP and S100 protein expressions in tumour cells from pituitary adenomas are influenced by hormone profile. Our results support the presence of two molecular subtypes of FS cells GFAP+/VEGF+/S100 respectively and another one that is GFAP-/S100+/ /EGFR+ simultaneously with the classical variant GFAP+/S100+. It is possible that S100+/EGFR+ pituitary adenomas represent a group of pituitary adenomas with an aggressive behaviour and a high ability of invasion and recurrence. (Endokrynol Pol 2017; 68 (4): 380-389)
Introduction
The normal pituitary gland is known to express a wide panel of immunohistochemical markers with a great heterogeneity of expression, which is region dependant. As has been experimentally demonstrated in specimens taken from the pars intermedia, ACTH type cells mostly express cytokeratins and vimentin [1] . All hormoneproducing cells are positive for cytokeratins, it appears that the folliculo-stellate cells from the adenohypophysis are selectively stained with CK19, while other regions contain EMA, sialomucin, and Leu7positive cells [1] . In a similar manner to the normal pituitary, adenomas show a differential expression of immunohistochemical markers. It has been demonstrated that most adenomas express cytokeratins [1] . In the same study, Kasper et al. [1] showed that coexpression of vimentin and neurofilament protein is rare in pituitary adenomas. Also, unlike the normal hypophysis, pituitary adenomas are negative for EMA and sialomucin but present an increased Leu7 expression, which is encountered in the GH type and prolactin type of pituitary adenomas. Protein S100 and the glial fibrillary acidic protein (GFAP) in pituitary adenomas have been little studied. It appears that folliculo-stellate cells are positive for these two markers, most probably due to their glial origin [2] . It has been demonstrated that S100 protein is also expressed by the epithelial cells that line Rathke cysts and by some cells located in the pars tuberalis [2] . Moreover, a limited number of cells from Rathke cysts seem to co-express cytokeratins, protein S100, and GFAP, an aspect that is sometimes related to neoplastic changes [2] . Carcinogenesis in the pituitary gland seems to be enhanced by TNFalpha and IL6, as has been shown in invasive pituitary adenomas [3] . Other differential expressions have been noticed in ACTH type adenomas. It appears that these tumours present a diffuse positive reaction for CK20 and CK7, while TTF1 expression was considered insignificant [4] . Only a few scattered literature data are found regarding the expression of protein S100 and GFAP in pituitary adenomas, but lot of information is available regarding their expression in tumours of the neurohypophysis [5] [6] [7] [8] . Their expression in the pituitary tissue is limited to their description in the folliculo-stellate cells as well as in relation to the stem cells of the anterior pituitary gland. Folliculo-stellate cells are known to be controversial histological and pathological entities in both humans and mammals [9] [10] [11] . Folliculostellate cells have been reported as reactive players in pituitary adenomas [9] and possess a heterogenous S100 and GFAP expression, thus leading to the classification of subgroups with different phenotypes. It appears that, besides their role as sustentacular cells of the adenohypophysis, folliculo-stellate cells are characterised by a great plasticity and possess the ability to modulate the hypothalamo-hypophyseal-adrenal axis in special conditions [11, 12] . In spindle cell oncocytoma, a discussed pathologic entity, which seems to originate from folliculo-stellate cells, tumour cells are positive for S100 but, surprisingly, negative for GFAP [13] [14] [15] . Unlike spindle cell oncocytomas and adenomas of the anterior hypophysis, the adamantinomatous type of craniopharyngioma exhibits a positive GFAP reaction, while other tumour types appear to be negative for both S100 protein and GFAP but positive for TTF1 [16, 17] . GFAP, a marker of the neuroendocrine system, is strongly expressed in the neurohypophysis, namely by the granular cells and by the filament containing cells belonging to the choristoma, probably due to the fact that both cell types emerge from astrocytes [18] . S100 protein and GFAP expression in the tumour cells of pituitary adenomas is less studied, and the implication of these factors in the evolution and pathogenesis of pituitary adenomas has little been correlated with other prognostic or therapeutic factors that have previously been studied in pituitary adenomas. Besides protein S100 and GFAP, the neuroglial antigen 2 (NG2) is another controversial marker in tumours of the pituitary gland. Normally, NG2 is expressed by oligodendrocytes progenitors, pericytes, and tumour cells [19] . In pathological situations, this marker is exhibited by all tumour types of the adenohypophysis except for the ACTH type [19] . It has also been demonstrated that NG2 modulates the prolactin type and the GH type adenomas through enhancement of cell adhesion but without influencing proliferation [19] . Previous data available in literature regarding pituitary pathology shows that a molecular mapping of the normal hypophysis, and of the various tumour types that emerge from it, serves as a useful tool for differential diagnosis and for the diagnosis of ectopic hormone-producing tissue and of metastases [20] . Based on these scattered literature data, the research that has been led in the present study has been initiated with the purpose of elucidating the implication of protein S100 and GFAP in the evolution and prognosis of pituitary adenomas, and to establish the correlation of their expression with different growth factors known as prognostic and/or therapeutic markers in several types of tumours but, also, less investigated in pituitary adenomas.
Material and methods
For our retrospective study, we selected 61 paraffin embedded specimens of pituitary adenomas based on accurate criteria regarding the pre-analytical stages, which included fixation, paraffin embedding proce-dures, and three-micrometer serial section performance. Histopathologic reevaluation was performed by three experienced pathologists who examined the haematoxylin and eosin-stained slides and selected six additional sections from each case to establish the hormone profile of pituitary adenomas, growth hormone (GH), prolactin (PRL), adrenocorticotropic hormone (ACTH), thyroid stimulating hormone (TSH), folliculostimulating hormone (FSH), and luteinising hormone (LH). Immunohistochemical procedures were performed to highlight all six pituitary hormones, i.e. growth hormone (GH, polyclonal rabbit antihuman, dilution 1 : 300), prolactin (PRL, polyclonal rabbit anti human, dilution 1 : 250), adrenocorticotropin (ACTH, monoclonal mouse antihuman, clone 02A3, dilution 1 : 50), thyroid stimulating hormone (TSH, monoclonal mouse antihuman, clone 0042, dilution 1 : 50), luteinizing hormone (LH, monoclonal mouse antihuman, clone C93, dilution 1 : 50), and follicle stimulating hormone (FSH, monoclonal mouse antihuman, clone C10, dilution 1 : 50). All primary antibodies were supplied by Dako Cytomation, Carpinteria, USA.
Glial fibrillary acidic protein (monoclonal mouse anti human, clone GA5, ready to use, Novocastra) and S100 protein (rabbit polyclonal, Novocastra) were also performed by immunohistochemistry. All steps of immunohistochemical procedures were performed in an automated manner by using Bond Max Autostainer (Leica, Microsystems), having well standardised protocols specific for each antibody included in the present study.
Microscopic evaluation was made by two independent observers using a Nikon Eclipse E600 microscope (Nikon Corporation Japan). The images were captured and processed using a Lucia G system. For the evaluation of the hormone profile, more than 10% positive cells was considered a secreting tumour. Tumours presenting an increased GH, PRL expression were considered as a mamosomatotroph. GFAP and S100 protein were evaluated both in tumour cells and folliculostellate cells of the pituitary adenomas. Their expression was correlated with hormone profile and epidermal growth factor receptor (EGFR) previously studied on the same cases, and considering a potential therapeutic target for several tumours. Statistical analysis was made using the SPSS system version 17. The statistical methods included correlation tests such as Pearson, Kendall, and Spearman. The correlations were considered statistically significant if the p value was less than 0.05. A total correlation was considered when all three test groups presented significant values, and a partial correlation was considered when two out of three correlation tests presented statistical significance.
Results
GFAP expression was immunohistochemically quantified in the normal pituitary gland and in pituitary adenomas. GFAP heterogeneous expression correlated with the cell types and its distribution has been demonstrated. Initially, GFAP expression was described in the normal pituitary gland. Regarding the expression pattern, we encountered a cytoplasmic distribution of GFAP and a cytoplasmic combined with a membranar pattern in both endocrine and folliculo-stellate cells (FS) (Fig. 1a, b, c) . In the acidophilic cells, GFAP was weakly expressed in the cytoplasm rarely with a membranar pattern. Inserted amongst these cell types, intensely positive cells were observed, with a chromophobe and basophilic morphology. FS were distributed amongst the endocrine cells but closely related to and surrounding capillary vessels and, as expected, had a different morphology with rare and short expansions that were strongly interconnected with the wall of the capillary vessel. FS cells were discontinuously distributed around the fenestrated capillary vessels, the contact between these cells and the capillary wall being made only through the expansions of the FS cells (Fig. 1d ). FS cells density was relatively low, 2-4 cells/capillary vessel being observed. A particular aspect was observed in the area of the tuberal portion of the pituitary gland where the cells that lined the pseudofollicular structures were intensely positive for GFAP (Fig. 1e) . Pituitary adenomas were characterised by a higher GFAP expression, compared with normal pituitary gland, but with the same distribution both in the tumour endocrine cells and in the FS cells, respectively.
From the total number of cases included in the study, 43.33% had a positive reaction for GFAP in tumour cells with low or moderate expression, with a strictly cytoplasmic location. The intensity of GFAP expression in FS cells was similar to that found in FS cells from the normal pituitary gland, but their number increased substantially compared with normal pituitary gland.
The distribution of GFAPpositive FS cells (GFAP + FS cells) was dependent on the hormone profile of the adenomas included in the study. Thus, in the adenomas with a GH or GHPRL combined profile, the FS cells had a low density, being inserted amongst the tumour cells (Fig. 2a ) that presented a low or moderate positive reaction for the same marker (Fig. 2b) . In chromophobe cell adenomas, tumour cells were negative for GFAP, the intensity and the density of GFAP +FS cells being high. For ACTH secreting adenomas, GFAP expression was restricted to the FS cells that presented a particular distribution, tumour cells being negative. An increase in the density of GFAP + FS cells was observed compared with normal pituitary gland. Their distribution was also specific; namely, they
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The presence of GFAP+ FS cells in the normal pituitary tissue and in pituitary adenomas revealed a morphological heterogeneity that was dependent not only on the normal or the tumour status but also on the hormone profile of pituitary adenomas. Thus, in the normal pituitary tissue, GFAP+ FS cells had an elongated cell body and presented short and rare expansions, interposed amongst endocrine cells or attached to the capillary wall (Fig. 2e , inset) compared with GH secreting pituitary adenomas, where GFAP+ FS cells presented an irregular body, mostly with a triangular aspect, with rare expansions, strongly attached to the adenoma tumour cells.
Starting from the microscopic observation of the morphological heterogeneity of the GFAP+ FS cells, we continued the study with the assessment of the correlation between GFAP expression and the hormone profile of pituitary adenomas, to identify the potential were grouped around the blood vessels, with a tendency to form a relatively continuous layer around the capillary vessels (Fig. 2c) . ACTHsecreting pituitary adenomas were characterised by the presence of vascular spaces, apparently not lined by endothelial cells, with the wall composed of tumour cells and palisading GFAP + FS cells (Fig. 2d) . GFAP + FS cells belonging to ACTHsecreting adenomas presented an oval, elongated cell body that was inserted amongst tumour cells, with a characteristic "palisade-like" distribution, and which had the tendency to give sprouting expansions only from the cell pole opposite to the vascular or pseudo-vascular lumen.
The highest density of GFAP + FS cells was observed in plurihormonal pituitary adenomas, predominantly in the papillary type. GFAP+ FS cells formed in this case a well-organised network though the interrelation that they established with their cytoplasmic expansions (Fig. 2e) . (Table I) . A strong correlation was also registered between ACTH and GFAP expression, thus the correlation index was statistically significant, at 12 (Table IIa, b) . A low correlation was also present in that which considers LH (Table IIc) . Regarding the other molecular markers included in the study, we registered an inversed correlation between GFAP expression and that of oncoprotein HER2 (p = 0.025). EGFR overexpression did not significantly overlap GFAP expression from a statistical point of view (p = 0.072). On the other hand, we registered a very strong correlation between GFAP and VEGF overexpression in pituitary adenomas (p = 0.0014). S100 protein in pituitary adenomas was also studied by using the immunohistochemical method on the normal pituitary gland and in pituitary adenomas. S100 protein had a nuclear and cytoplasmic pattern, being positive in the FS cells but also in the endocrine cells of the normal pituitary gland and the adenoma ones. The combined nuclear/cytoplasmic pattern was observed in tumour cells for about 19 
Figure 1. GFAP expression pattern in the normal pituitary gland. The heterogeneity of expression between the nests of endocrine cells (a), followed by a cytoplasmic expression pattern or cytoplasmic and membranous combined (b). In the stellate follicular cells (FS), the expression was intense and homogenous (c). Stellate follicular cells surrounding the capillary vessels, with their expansions attached to

high density of FS cells, GFAP positive, in an LH-secreting pituitary adenoma (b). FS cells with a perivascular distribution (b) and with the tendency of forming, along with tumour cells, the wall that lines the pseudovascular spaces, characteristic for ACTH-secreting pituitary adenomas (c). The distribution of FS-GFAP+ cells in plurihormonal pituitary adenomas. Note the high density and the network-like disposition given by the interconnections between the numerous expansions of the FS-GFAP+ cells (d). The interposition of tumour cells between the FS-GFAP+ cell expansions and the wall of the capillary vessel, which suggests disruption of the blood-brain barrier (d, inset).
Rycina 2. Gruczolak przysadki wydzielający GH (a): słabo lub umiarkowanie GFAP-dodatnie komórki guza, między którymi widoczne są silnie GFAP-dodatnie komórki pęcherzykowato-gwiaździste. Gęsto ułożone GFAP-dodatnie komórki FS w gruczolaku przysadki wydzielającym LH (b). Komórki FS rozmieszczone wokół naczyń krwionośnych (b) z tendencją do formowania, wraz z komórkami guza, ścian tworzących przestrzenie imitujące naczynia krwionośne, co jest charakterystyczne dla gruczolaków przysadki wydzielających ACTH (c). Rozkład komórek FS-GFAP+ w gruczolakach plurihormonalnych. Należy zwrócić uwagę na dużą gęstość i sieciowy układ spowodowany połączeniami między licznymi rozrastającymi się komórkami FS-GFAP+ (d). Komórki guza znajdują się między rozrastającymi się komórkami FS-GFAP+ a ścianami naczyń krwionośnych, co sugeruje przerwanie bariery krew-mózg (d, wstawka)
. The expression of protein S100 in the normal pituitary gland. Note the intense, nuclear, and cytoplasmic expression in the stellate follicular cells and the moderate cytoplasm-restricted expression in the endocrine cells, with an acidophilic pattern on HE and a low intensity in chromophobe cells (a). The variability of protein S100 expression in GH-secreting pituitary adenomas: intense, nuclear, and cytoplasmic (b), intense, cytoplasmic (c). Chromophobe type pituitary adenoma with chromophobe cells negative for protein S100 in their cytoplasm, with a focal and heterogenous expression in the nuclei of the chromophobe cells and in the cytoplasm, and the nucleus of FS cells inserted amongst chromophobe cells
Rycina 3. Ekspresja białka S100 w prawidłowej przysadce. Należy zwrócić uwagę na silną ekspresję w jądrze i cytoplazmie komórek pęcherzykowo-gwiaździstych oraz umiarkowaną ekspresję ograniczoną do cytoplazmy w komórkach endokrynnych z wybarwieniem kwasochłonnym w preparatach barwionych HE i małą ekspresję w komórkach barwnikoopornych (a). Zróżnicowanie ekspresji białka S100 w gruczolakach przysadki wydzielających GH: silna ekspresja w jądrze komórkowym i cytoplazmie, (b) silna ekspresja w cytoplazmie. (c) Barwnikooporny gruczolak przysadki z komórkami barwnikoopornymi niewykazującymi cytoplazmatycznej ekspresji białka S100; widoczna ogniskowa, heterogenna ekspresja jądrowa w komórkach barwnikoopornych oraz ekspresja cytoplazmatyczna i jądrowa w komórkach FS znajdującymi się między komórkami barwnikoopornymi
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the remaining cases presenting a cytoplasmic-restricted expression.
The percentage of S100positive cases was 66.12% from the total number of cases. Amongst these, 39.02% presented a compact growth pattern, 39.04% were of papillary type, 9.75% presented a trabecular growth pattern, 4.87% spindleshaped, and 7.31% were of alveolar type. Papillary type pituitary adenomas registered the highest intensity of S100 protein expression in tumour cells. Except papillary type adenomas, in the majority of pituitary adenoma cases the intensity of the reaction was low and moderate, in comparison to the normal tissue (Fig. 3a) . 34.2% of S100positive cases are composed of acidophilic cells. Pituitary adenomas with basophilic cells represented 26.8% of S100positive cases, and for 39 % of cases the chromophobe component was present forming pure chromophobe pituitary adenomas or mixed chromophobe-acidophilic/basophilic pituitary adenomas.
Regarding the particularities of the immunohistochemical expression of S100 protein, we observed variabilities in the presence, the intensity, and the distribution of this marker in relation to the hormone profile. GHsecreting pituitary adenomas proved to be extremely heterogenous in that which considers the expression of protein S100 in tumour cells. The cases ranged from the absence of its expression in tumour cells to a low expression, strictly located in the cytoplasm (Fig. 3b) , or an intense expression in the entire tumour area, nuclear and cytoplasmic, or just cytoplasmic (Fig. 3c) . In the case of pituitary adenomas with chromophobe cells, the expression of S100 protein was low in the cytoplasm of the chromophobe cells, being mostly nuclear restricted (Fig. 3d) .
The particular aspect that we noticed regarding the expression of GFAP in ACTHsecreting pituitary adenomas repeated itself in the case of protein S100. Tumour cells were negative while, around the vascular spaces, S100-positive cells were distributed, having a nuclear and cytoplasmic expression, and morphology similar to that of GFAP+FS cells. The expansions of the S100+ FS cells were strongly attached to the wall of the blood vessels, being also interconnected each other. These interconnections created a network of S100-positive expansions amongst which tumour cells were distributed.
As in the case of GHsecreting pituitary adenomas, the endothelial cells of the vessels located close to S100--positive cells had a positive reaction for S100 protein with a nuclear distribution. In the rest of the tumour mass the S100-positive cells with a FS morphology were rarely encountered in ACTHsecreting pituitary adenomas.
In relation to the hormone profile, none of the six markers used for immunohistochemical profiling significantly correlated from a statistical point of view with S100 protein expression. Amongst the growth factors and corresponding receptors previously studied by our team, S100 protein significantly correlated with EGFR expression in the cases where S100 protein presented a moderate or intense expression.
Discussion
GFAP and S100 protein were studied in pituitary adenomas, being frequently associated with FS cells [21, 22] . Their expression in tumour cells, separately quantified in various types of pituitary adenomas, represents a sporadic subject in literature and, for this reason, the correlations with the prognosis, long-term survival, recurrences, and therapeutic implications are extremely unconvincing at present. Increasing data suggest the ability of tumour endocrine and non-endocrine cells to transdifferentiate themselves in FS cells where the two markers overlap in that which considers their immunohistochemical expression, these FS cells actually being considered as pluripotent stem cells [23] [24] [25] . The 'retrodifferentiation' phenomenon was observed and described especially in the case of ACTHsecreting pituitary adenomas [24] . In our study we also observed a particular aspect of distribution, localisation and GFAP and S100 expression in the case of ACTH secreting pituitary adenomas. FS cells, GFAP+/S100+ were distributed around the blood vessels or lined pseudovascular spaces. We noticed a slightly increased density of these cells through GFAP immunostaining compared to protein S100. This discrepancy was supported by statistical data that showed that only GFAP significantly correlated from a statistical point of view with the expression of ACTH, while S100 protein did not present any statistically significant correlation, despite the distribution and morphology concordance. This discrepancy of expression suggests two hypotheses: (i) the existence of two subpopulations of FS cells, an immature one that expresses only S100 with a great differentiation capacity and a population of mature FS cells GFAP+/S100+ with a well-established role, namely to establish the interconnection between the endocrine cells and the fenestrated capillary vessels, considering their distribution and localisation pre viously described correlated with the late expression of GFAP compared to S100 protein; and (ii) the existence of the same cell population but one that may present more than one evolutionary phase. These hypotheses will be demonstrated or infirmed through the quantification of the markers used to show pluripotent stem cells in further studies.
As a paradox, the description of S100 protein expression and that of GFAP in the normal pituitary gland is restricted to the evaluation of FS cells. We have not found any data in the literature regarding differential GFAP and S100 protein expression in the endocrine cells of the normal human pituitary gland.
Nowadays there is an experimental model that supports the data that we found, regarding the correlation between GFAP, ACTH, and LH. This model demonstrated that the induction of Bmi 1 overexpression by GFAP induced, in the experimental murine model, the development of pituitary adenomas in the anterior and intermediate portions of the adenohypophysis [26] . Over 50% of pituitary adenomas overexpress Bmi1 [26] , a percentage that overlaps with the percentage of GFAP + pituitary adenomas that we found in our study. It has been also demonstrated that such pituitary adenomas increase ACTH secretion, an aspect that is also in concordance with the data observed and quantified in the present study.
The statistically significant association between GFAP and VEGF did not come as a surprise, considering the fact that VEGF was initially isolated from the FS cells of bovine adenohypophysis [27] and, moreover, pituitary adenomas also expressed VEGF in the tumour cells. On the other hand, the lack of association between VEGF and protein S100 counterbalanced by the S100-EGFR association supports the presence of two distinct FS cell and adenoma cell populations with different functions and having a rather well defined prognostic and therapeutic role.
Moreover, S100EGFR association represents an unfavourable prognostic factor that stimulates the proliferation, invasion, and metastasis of tumour cells in hepatocellular carcinomas [28] , glioblastomas [29] , and melanomas [30] . Pituitary adenomas were not characterised from this point of view until now. Our data suggest the implication of this mechanism in GHsecreting pituitary adenomas and probably in PRL secreting ones also, but these data must be validated through further studies.
Conclusions
GFAP and protein S100 expression in tumour cells is implicated in the pathogenesis of the GHand PRL secreting pituitary adenomas, the mechanisms of activation being nowadays incompletely studied. This aspect seems to represent an unfavourable prognostic factor that governs the retro-differentiation phenomenon and supports the presence of pluripotent stem cells. Our results support the presence of two molecular subtypes of FS cells GFAP+/VEGF+/S100 respectively and another one that is GFAP-/S100+/EGFR+ simultaneously with the classical variant GFAP+/S100+. Through analogy with the observations obtained in other tumour types, it is possible that S100+/EGFR+ pituitary adenomas represent a group of pituitary adenomas with aggressive behaviour and a high ability of invasion and recurrence, aspects that represent an unfavourable prognostic factor. The GFAPACTHLH axis is studied only in experimental models presently, but it seems to favour the development of pituitary adenomas in the anterior and intermediate regions of the adenohypophysis, adenomas that are characterised by an unfavourable prognosis.
